Skip to content

Serotonin research published in 2023

Page 3 of 5: studies 41 to 60 of 91, newest first. Back to the serotonin overview

Studies

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice

Research Square July 7, 2023 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 4 citations preprint

Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...

Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparations.

Naunyn-Schmiedeberg's Archives of Pharmacology July 1, 2023 Joachim Neumann, Nils Schulz, Charlotte Fehse et al. 13 citations

It is unclear whether bufotenin (= N,N-dimethyl-serotonin = 5-hydroxy-N,N-dimethyl-tryptamine), a hallucinogenic drug, can act on human cardiac serotonin 5-HT4 receptors. Therefore, the aim of the study was to examine the cardiac effects of bufotenin and for comparison tryptamine in transgenic mice that only express the human 5-HT4 receptor in cardiomyocytes (5-HT4-TG), in their wild-type...

Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging July 1, 2023 Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al. 18 citations

Lysergic acid diethylamide (LSD) is an atypical psychedelic compound that exerts its effects through pleiotropic actions, mainly involving 1A/2A serotoninergic (5-HT) receptor subtypes. However, the mechanisms by which LSD promotes a reorganization of the brain's functional activity and connectivity are still partially unknown. Our study analyzed resting-state functional magnetic resonance...

Prepulse inhibition of the acoustic startle reflex impairment by 5-HT2A receptor activation in the inferior colliculus is prevented by GABAA receptor blockade in the pedunculopontine tegmental nucleus.

Behavioural Brain Research June 25, 2023 Rodolpho Pereira de Oliveira, Thaís S. Yokoyama, Lucas de Santana Cardoso Thomaz et al. 2 citations

The relationship between serotonin dysfunction and schizophrenia commenced with the discovery of the effects of lysergic acid diethylamide (LSD) that has high affinity for 5-HT2A receptors. Activation of these receptors produces perceptual and behavioural changes such as illusions, visual hallucinations and locomotor hyperactivity. Using prepulse inhibition (PPI) of the acoustic startle, which...

DOI: 10.1016/j.bbr.2023.114436 (opens in new tab) Full text (opens in new tab) Gaba Inferior colliculus Pedunculopontine tegmental nucleus Prepulse inhibition +5

Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats

Frontiers in Neuroscience June 22, 2023 Filip Tylš, Čestmír Vejmola, Vlastimil Koudelka et al. 9 citations

Introduction Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT 2A receptors, it has high binding affinity also to 5-HT 2C and 5-HT 1A receptors and indirectly modulates the dopaminergic system. Psilocybin and its active metabolite psilocin, as well as other...

The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models

Psychopharmacology June 13, 2023 Mariusz Papp, Piotr Gruca, Magdalena Lason et al.

NLX-101 and NLX-204 are highly selective serotonin 5-HT1A ‘biased’ agonists, displaying potent and efficacious antidepressant-like activity upon acute administration in models such as the forced swim test. we compared the effects of repeated administration of NLX-101, NLX-204 and ketamine in the chronic mild stress (CMS) model of depression, considered to have high translational potential, on...

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Journal of Psychopharmacology June 8, 2023 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 60 citations

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period. Aims: To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both...

Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex.

The International Journal of Neuropsychopharmacology June 1, 2023 Josua Zimmermann, Niklaus Zölch, Rebecca C Coray et al.

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely used recreational substance inducing acute release of serotonin. Previous studies in chronic MDMA users demonstrated selective adaptations in the serotonin system, which were assumed to be associated with cognitive deficits. However, serotonin functions are strongly entangled with glutamate as well as γ-aminobutyric acid (GABA)...

The effects of serotonergic psychedelics in synaptic and intrinsic properties of neurons in layer II/III of the orbitofrontal cortex.

Psychopharmacology June 1, 2023 Zi-Hang Tang, Zhi-Peng Yu, Qiong Li et al. 7 citations

Serotonergic psychedelics show promise in the treatment of psychiatric disorders, including obsessive-compulsive disorder. Dysfunction of the orbitofrontal cortex (OFc) has been implicated in the pathophysiology of compulsive behavior, which might be a key region for the efficacy of psychedelics. However, the effects of psychedelics on the neural activities and local excitation/inhibition (E/I)...

DOI: 10.1007/s00213-023-06366-y (opens in new tab) Full text (opens in new tab) 5-ht2a receptor Excitation/inhibition balance Orbitofrontal cortex Psychedelics

The evolution and ecology of psilocybin in nature.

Fungal Genetics and Biology June 1, 2023 Matthew Meyer, Jason C. Slot 28 citations

Fungi produce diverse metabolites that can have antimicrobial, antifungal, antifeedant, or psychoactive properties. Among these metabolites are the tryptamine-derived compounds psilocybin, its precursors, and natural derivatives (collectively referred to as psiloids), which have played significant roles in human society and culture. The high allocation of nitrogen to psiloids in mushrooms,...

DOI: 10.1016/j.fgb.2023.103812 (opens in new tab) Full text (opens in new tab) Serotonin Evolutionary chemical ecology Specialized metabolites Fungi mushrooms +6

Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition

Clinical Pharmacology & Therapeutics May 30, 2023 Pablo Mallaroni, Riccardo Paci, Sabrina Ritscher et al. 34 citations

2,5‐dimethoxy‐4‐bromophenethylamine (2C‐B) is a hallucinogenic phenethylamine derived from mescaline. Observational and preclinical data have suggested it to be capable of producing both subjective and emotional effects on par with other classical psychedelics and entactogens. Whereas it is the most prevalently used novel serotonergic hallucinogen to date, it's acute effects and distinctions...

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience

bioRxiv (Cold Spring Harbor Laboratory) May 12, 2023 S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 18 citations preprint

Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...

Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.

Cell May 11, 2023 Isha Singh, Anubha Seth, Christian B. Billesbølle et al. 97 citations

The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has unusual anti-depressant and substance-withdrawal effects, and stabilizes the inward-open conformation. Unfortunately, ibogaine's promiscuity...

New psychoactive substances: kratom, DMT, serotonergic hallucinogens, dissociative drugs. The mechanism of action, psychoactive effects

Neurology Bulletin May 10, 2023 Andrey V. Antsyborov

Through the times of human culture there was a desire of using various chemical compounds, obtained from both natural plant material and artificially synthesized, for recreational purposes. These substances can cause changes in the mental state, influence the human behavior, change social activity. The review is devoted to NPS, which have only been thoroughly studied in recent years. These...

Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder.

Translational Psychiatry May 10, 2023 Sandeep Singh, Alexander Botvinnik, Orr Shahar et al. 54 citations

Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder. However, the receptor mechanisms implicated in the putative anti-obsessional effect are not clear. On this background, we set out to explore (1) the role of serotonin 2A (5-HT2A) and serotonin...

DOI: 10.1038/s41398-023-02456-9 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Behavioral research Pharmacology

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.

Journal of Psychiatric Research May 1, 2023 Franklin R. Schneier, Jamie D. Feusner, Michael G. Wheaton et al. 79 citations

Body dysmorphic disorder (BDD) is an often-severe condition in which individuals are preoccupied by misperceptions of their appearance as defective or ugly. Only serotonin reuptake inhibitors and cognitive-behavioral therapy have been demonstrated efficacious in randomized controlled trials. Psilocybin is a psychedelic drug with growing evidence for safety and efficacy in treatment of...

DOI: 10.1016/j.jpsychires.2023.03.031 (opens in new tab) Full text (opens in new tab) Psilocybin Body dysmorphic disorder Clinical trial Psychedelic treatment +4

Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence

Trends in Psychiatry and Psychotherapy May 1, 2023 Elena Koning, Elisa Brietzke 13 citations

Eating disorders (ED) are a group of potentially severe mental disorders characterized by abnormal energy balance, cognitive dysfunction, and emotional distress. Cognitive inflexibility is a major challenge to successful ED treatment and dysregulated serotonergic function has been implicated in this symptomatic dimension. Moreover, there are few effective treatment options and long-term...

Multi-state Model-Based Identification of Cryptic Allosteric Sites on Human Serotonin Transporter

ACS Chemical Neuroscience April 17, 2023 Gao Tu, Binbin Xu, Ding Luo et al. 15 citations

Serotonin transporter (SERT) plays a fundamental role in taking the synaptic cleft serotonin back to the presynaptic neuron. The discovery of allosteric SERT modulators represents the next-generation medication for psychiatric disorders such as depression. Here, based on the cryo-EM structures of ibogaine in complex with SERT in distinct conformations, the multiple functional structures of the...

A whole-brain model of the neural entropy increase elicited by psychedelic drugs.

Scientific Reports April 17, 2023 Rubén Herzog, Pedro A. M. Mediano, Fernando E. Rosas et al. 51 citations

Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in subjective experience, and provide a unique opportunity to study the neurobiological basis of consciousness. One of the most notable neurophysiological signatures of psychedelics, increased entropy in spontaneous neural activity, is thought to be of...